Trial Profile

Study to Evaluate the Induction of HBV Virus Neutralizing Antibodies in Healthy Vaccine Naive Adults and Non-responders and in Patients Chronically Infected With HBV Using VVX001

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VVX 001 (Primary)
Indications Hepatitis B
Focus Pharmacodynamics
Sponsors Viravaxx

Most Recent Events

30 Jan 2024 According to a Viravaxx medial release , the final report(n=64) of the phase 2 study VVX001-CS001 confirming the preliminary analysis performed earlier, has been published.
30 Jan 2024 According to a Viravaxx medial release , Primary endpoint (PreS specific IgG antibodies) has been met.
26 Jun 2022 Results presented at The International Liver Congress 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com